Chlormezanone

HCID 2717

Basic information

CAS
102818-66-6
Standard SMILES
CN1C(=O)CCS(=O)(=O)C1c1ccc(Cl)cc1
InChIKey
WEQAYVWKMWHEJO-UHFFFAOYSA-N
Molecular formula
C11H12ClNO3S
Average molar mass
273.74 g/mol
Monoisotopic mass
273.02264192

Overview

Chlormezanone is a 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions. It has a role as an anxiolytic drug, an antipsychotic agent and a muscle relaxant. It is a lactam, a sulfone, a 1,3-thiazine and a member of monochlorobenzenes.

Names & identifiers

Preferred name
Chlormezanone
IUPAC
2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one
English name
Chlormezanone
Molecular formula
C11H12ClNO3S
Molecular weight
273.74

Names & synonyms

chlormezanone80-77-3ChlormethazanoneTrancopalChlormethazoneChlormezanonClormetazanoneClormetazonPhenaroldl-ChlormezanoneBanabinClorilax
Show more names
LobakRilaxAlinamMuskelwin4692FENAROLMio-Sed
MiorilaxRilansylRilaquilRilassolSupotranTanafolBisinaRexan

Database identifiers

CAS
102818-66-6、102818-67-7、80-77-3
PubChem CID
2717
DTXSID
DTXSID3022798
ChEMBL
CHEMBL1200714
ChEBI
CHEBI:3619
UNII
4BU37OM8KL、C14WB33Y0S、GP568V9G19
EC Number
201-307-4

Properties

Computed structural properties

XLogP
1.1
Topological polar surface area
62.8 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
3
Rotatable bonds
1
Heavy atoms
17

Experimental & physicochemical properties

LogP1.3
Color/FormCRYSTALS
Solubility · 3 items

SOL (% WT/VOL) @ 25 °C: LESS THAN 0.25% IN WATER, LESS THAN 1.0% IN 95% ETHANOL

FREELY SOL IN CHLOROFORM; SLIGHTLY SOL IN DIETHYL ETHER; SPARINGLY SOL IN N-HEXANE

1.61e+00 g/L

Human Drugs · 3 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point · 3 items

116.2-118.6

116.2-118.2 °C

116.2 °C

Physical DescriptionSolid

Physicochemical properties

Melting point
114 °C · 114 °C
Boiling point
534.5 · 534.5±50.0 °C(Predicted)
Density
1.2205 · 1.2205 (rough estimate)
refractive index
1.63 · 1.6300 (estimate)
storage temp.
Sealed in dry,Room Temperature
solubility
Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)

Safety & regulation

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 4 reports by companies from 2 notifications to the ECHA C&L Inventory.

Hazard information

Other Safety InformationIMAP assessments - 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxicology

Interactions · 1 item

CHLORMEZANONE MAY LOWER TOLERANCE OF PATIENTS TO ALCOHOL...POSSIBLE ADDITIVE EFFECTS /WITH CHLORMEZANONE &/ CNS DEPRESSANTS SUCH AS ALCOHOL, PHENOTHIAZINES, BARBITURATES, NARCOTICS, OTHER PSYCHOTHERAPEUTIC AGENTS, & MONOAMINE OXIDASE INHIBITORS.

Toxicity Summary · 1 item

Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.

Signs and SymptomsSymptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.
Human Toxicity Excerpts · 4 items

...COMMONLY PRODUCE DROWSINESS, DIZZINESS, HEADACHE, BLURRED VISION, WEAKNESS, LETHARGY, ATAXIA, & NYSTAGMUS. NAUSEA, VOMITING, HEARTBURN, & ABDOMINAL DISTRESS...ESP AFTER LARGE ORAL DOES. ...SKIN RASH & PRURITUS &, RARELY, ANAPHYLACTOID REACTIONS & LEUKOPENIA. /CENTRALLY ACTING MUSCLE RELAXANTS/

INCIDENCE OF UNTOWARD REACTIONS IS ABOUT 3% & MINOR IN NATURE...MALAISE, EXCITEMENT... PETECHIAE, OR ECCHYMOSES SOMETIMES DEVELOP; LIVER DAMAGE...OR ANGIONEUROTIC EDEMA ARE RARE.

LETHARGY & FLUSHING HAVE BEEN OBSERVED & JAUNDICE HAS OCCURRED RARELY.

...ORAL TOXICITY LESS THAN MEPROBAMATE, ZOXAZOLAMINE, OR METHOCARBAMOL. ... IN CLINICAL TRIALS ONLY 2.3% OF 4653 PT HAS SIDE EFFECTS... OVERDOSAGE UP TO 10 G HAS NOT CAUSED DEATH. EVEN LARGE AMT PRODUCE ONLY MILD SIDE EFFECTS.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Chlormezanone

vMost-DILI-concern

8

Withdrawn

DOI:10.1016/j.drudis.2016.02.015

Safety data

rtecs
XJ1050000
hs_code
2934.99.4400
Signal word
Warning
Symbol(GHS)
GHS07
Storage Class
11 - Combustible Solids
Hazard statements
H302

Chemistry & industry

Pharmacology

ATC Code · 2 items

M - Musculo-skeletal system

QM - Musculo-skeletal system

PharmacodynamicsChlormezanone is a non-benzodiazepine muscle relaxant. It was discontinued worldwide in 1996 by its manufacturer due to confirmed serious and rare cutaneous reactions (toxic epidermal necrolysis).
Mechanism of Action · 3 items

Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.

NEURONAL CONDUCTION, NEUROMUSCULAR TRANSMISSION, & MUSCLE EXCITABILITY ARE NOT DEPRESSED EXCEPT AFTER NEARLY LETHAL DOSES. PROMINENT EFFECT...IS TO DEPRESS SPINAL POLYSYNAPTIC REFLEXES PREFERENTIALLY OVER MONOSYNAPTIC REFLEXES. /CENTRALLY ACTING MUSCLE RELAXANTS/

IN ABSENCE OF DEFINITIVE STUDIES IT APPEARS REASONABLE TO ASCRIBE BENEFICIAL EFFECTS...TO THEIR SEDATIVE PROPERTIES. /CENTRALLY ACTING MUSCLE RELAXANTS/

Metabolism/Metabolites · 2 items

CHLORMEZANONE...IS EXCRETED UNCHANGED IN HUMAN URINE & DOG BILE. FORMATION OF 4-CHLOROHIPPURIC ACID, MAJOR URINARY METABOLITE IN MAN, INVOLVES NON-ENZYMIC HYDROLYSIS, FOLLOWED BY OXIDATION & CONJUGATION OF 4-CHLOROBENZALDEHYDE PRODUCT OF HYDROLYSIS.

(14)C-CHLORMEZANONE, METABOLITES IN URINE OF RATS & MICE WERE P-CHLOROBENZOIC ACID, P-CHLOROHIPPURIC ACID, N-METHYL-P-CHLOROBENZAMIDE, 2-[N-METHYL-N-(P-CHLOROBENZOYL)]CARBAMOYLETHYLSULFONIC ACID, 3-SULFOPROPIONIC ACID & GLUCURONIDE OF P-CHLOROBENZOIC ACID.

MeSH Pharmacological Classification · 2 items

A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358)

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Absorption, Distribution and Excretion · 2 items

RAPIDLY ABSORBED FROM GI TRACT...EFFECT WITHIN 15 TO 30 MIN...DURATION OF ACTION OF 4 TO 6 HR...FREE DRUG & /4-CHLOROHIPPURIC ACID/ EXCRETED IN URINE /HUMAN, ORAL/...PRESENT IN HIGH CONCN IN KIDNEY, LIVER, MUSCLE, HEART, & BODY FAT, & IN LESSER CONCN IN LUNG & PLASMA /RATS, ORAL/.

AFTER ORAL ADMIN OF (14)C-CHLORMEZANONE, ABOUT 74% OF DOSE WAS EXCRETED INTO URINE OF RATS WITHIN 24 HR & 21% INTO URINE OF MICE WITHIN 2 HR. BILIARY EXCRETION OF RADIOACTIVITY WAS ABOUT 10% OF DOSE IN RATS.

Uses & manufacturing

Uses · 2 items

MEDICATION

Used in the management of anxiety and in the treatment of muscle spasm.

Methods of ManufacturingPREPN STARTING WITH 4-CHLOROBENZYLIDENEMETHYLAMINE: SURREY ET AL, J AM CHEM SOC 80, 3469 (1958): BRIT PAT 815,203 (1959 TO STERLING DRUG).
Formulations/PreparationsORAL: TABLETS 100 & 200 MG
Use ClassificationPharmaceuticals
Applications · 3 items

UsesSkeletal muscle relaxant

UsesChlormezanone improves the emotional state of the patient, relieving moderate anxiety and stress. However, it has a number of side effects, and because it does not have any advantage over other anxiolytics, it is rarely used in practice.

UsesThe use of chlormezanone is associated with large increases in the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Upstream & downstream products

Suppliers94 total

梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
阿诺西(上海)生物技术有限公司400-1107768 15058188853 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]
上海麦克林生化科技股份有限公司021-50706066 15221275939 · [email protected]
Additional notes · 1 item

DefinitionChEBI: A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.

Related reactions

0 records

No reaction records under the current filter.

Compound notes

Loading…